The Esketamine (Spravato) Price Index (2026)
Esketamine has different economics from private ketamine: certified centers, insurer billing — and in most countries no consumer price at all. Where a number is published, it is here.
| Country | Published session price | Reimbursed? | Last verified |
|---|---|---|---|
| Germany # | list price ~€345 per 28 mg device; a four-week self-pay induction can reach ~€8,000 before clinic fees | Yes: GKV for on-label TRD, incl. office-based practices (GOP 01549) | |
| Austria # | €150–250 per private esketamine session (published practice fee); Wahlarzt refund typically €80–110 | Partially, inpatient via hospital financing; outpatient case-by-case | |
| Sweden # | drug cost to the region: 2,089 SEK (28 mg) / 4,179 SEK (56 mg) / 6,269 SEK (84 mg) per session; patient pays standard fees within the high-cost ceiling | Restrained: NT Council advises 'strongly restrained' use; regions decide | |
| Poland # | no consumer price, fully funded via NFZ B.147 (drug, administration, observation and monitoring) | Yes, free for eligible patients, max 34 weeks |
Almost everywhere else there is no consumer price — in the Netherlands, Switzerland, Italy, Ireland, Spain, Portugal, Finland, Denmark and Belgium, Spravato is paid for by the public system for eligible patients; you pay standard co-payments at most. Criteria and process, country by country: the reimbursement map.
Why the covered route matters: at Germany's list price of roughly €345 per 28 mg device, a four-week self-pay induction can reach ~€8,000 — before clinic fees. The comparison with private racemic ketamine lives in the ketamine cost index; the clinical comparison of the two substances in the Spravato vs ketamine guide.